2021 · Journal of pharmaceutical and biomedical analysis · paywalled
Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validation
Braal et al.
The finding, in our words
An LC-MS/MS method for ribociclib in dried blood spots met FDA validation criteria, demonstrating strong correlation with plasma (R² 0.97) in 17 advanced breast cancer patients; 71% of DBS results fell within 20% of plasma values and haematocrit (0.20–0.40 L/L) did not affect validation. This enables decentralised therapeutic drug monitoring for oncology patients via patient-centric microsampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
The authors developed and validated an LC-MS/MS method for measuring three PARP inhibitors in both plasma and dried blood spots. They found strong agreement between the two matrices for olaparib and niraparib, suggesting DBS could support therapeutic drug monitoring for these oncology drugs in decentralised settings.
Researchers developed and validated a dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib and letrozole in breast cancer patients. Finger-prick samples showed strong correlation with plasma concentrations and remained stable at room temperature for 2.5 months, offering a decentralised approach to optimise drug dosing.
Poetto et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗
The study validated an LC-MS/MS method for eight antiepileptic drugs and two metabolites in dried blood spot and VAMS formats, with satisfactory analytical performance and stability, and was the first to include the oxcarbazepine metabolite DHCB. In 80 paired patient samples, microsampling concentrations showed promising correlation with plasma, supporting decentralised therapeutic drug monitoring of antiepileptic treatment.
Cobo-Golpe et al., Journal of analytical toxicology · source ↗